Business Context and Reporting Period
This Form 6-K is filed by pSivida Limited, a foreign issuer, for the month of May 2005. The report was signed on May 18, 2005, by Aaron Finlay, Chief Financial Officer and Company Secretary. The registrant's principal executive offices are located in Perth, Western Australia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change reported is the announcement of "Excellent Results from First Stage of POC Study with Epitan," as detailed in Exhibit 99.1. No financial comparisons to prior periods are included in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the positive outcome of the Proof of Concept (POC) study for the product Epitan. The filing does not contain specific forward-looking guidance, risk factors, contingencies, or details on unusual items beyond the study results.
Investor Verification Checklist
- Verify the full details and clinical significance of the Epitan POC study results referenced in Exhibit 99.1.
- Confirm the current regulatory status of Epitan following the reported study stage.
- Review subsequent filings for financial impact or updated guidance related to this study.